

# Carol Moreno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8748525/publications.pdf>

Version: 2024-02-01

105  
papers

5,961  
citations

147801

31  
h-index

74163

75  
g-index

105  
all docs

105  
docs citations

105  
times ranked

4451  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	27.0	1,427
2	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 43-56.	10.7	448
3	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020, 34, 787-798.	7.2	321
4	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	4.1	305
5	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	1.4	197
6	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. <i>Blood</i> , 2014, 124, 3841-3849.	1.4	185
7	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019, 133, 2031-2042.	1.4	178
8	Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 3433-3438.	1.6	137
9	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 121-128.	1.5	133
10	Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Cl�nic of Barcelona experience. <i>Blood</i> , 2009, 114, 2044-2050.	1.4	132
11	In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2009, 114, 4832-4842.	1.4	132
12	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2006, 107, 4563-4569.	1.4	130
13	Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. <i>Blood</i> , 2010, 116, 4771-4776.	1.4	126
14	New prognostic markers in chronic lymphocytic leukemia. <i>Blood Reviews</i> , 2008, 22, 211-219.	5.7	118
15	Chronic lymphocytic leukemia and autoimmunity: a systematic review. <i>Haematologica</i> , 2011, 96, 752-761.	3.5	117
16	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3853-3865.	1.6	115
17	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017, 129, 2612-2615.	1.4	111
18	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.	3.5	111

#	ARTICLE	IF	CITATIONS
19	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3440-3450.	5.2	91
20	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019, 3, 1799-1807.	5.2	90
21	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
22	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. <i>Blood</i> , 2018, 132, 892-902.	1.4	83
23	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. <i>Blood</i> , 2022, 139, 3278-3289.	1.4	83
24	Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. <i>Blood</i> , 2022, 139, 3278-3289.		66
25	Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. <i>Haematologica</i> , 2018, 103, 698-706.	3.5	63
26	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 648-657.e15.	0.4	62
27	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III ILLUMINATE trial. <i>Haematologica</i> , 2022, 107, 2108-2120.	3.5	53
28	Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. <i>British Journal of Haematology</i> , 2018, 180, 666-679.	2.5	51
29	Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. <i>Oncotarget</i> , 2017, 8, 54297-54303.	1.8	44
30	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , 2015, 100, 511-516.	3.5	42
31	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.	1.4	36
32	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 715-722.e6.	0.4	35
33	B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. <i>British Journal of Haematology</i> , 2014, 164, 570-578.	2.5	32
34	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 803-813.e7.	0.4	32
35	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2020, 136, 16-17.	1.4	32
36	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. <i>Clinical Cancer Research</i> , 2020, 26, 2096-2103.	7.0	31

#	ARTICLE	IF	CITATIONS
37	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	3.5	30
38	Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with <i>TP53</i> aberrations: a pooled analysis from four clinical trials. <i>British Journal of Haematology</i> , 2022, 196, 947-953.	2.5	28
39	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with <i>CLL</i> : a retrospective analysis from the European Society for Blood and Marrow Transplantation ( <i>EBMT</i> ). <i>British Journal of Haematology</i> , 2017, 178, 521-533.	2.5	26
40	CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 143-148.	1.5	26
41	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	4.1	24
42	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 3331-3331.	1.4	24
43	B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. <i>Leukemia and Lymphoma</i> , 2009, 50, 1075-1082.	1.3	20
44	First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study. <i>Blood</i> , 2021, 138, 70-70.	1.4	20
45	Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond <i>TP53</i> gene analysis can we go?. <i>Haematologica</i> , 2016, 101, 263-265.	3.5	19
46	Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With <i>TP53</i> Aberrations ( <i>del(17p)</i> or <i>TP53</i> Mutation): A Pooled Analysis From 4 Clinical Trials. <i>Blood</i> , 2020, 136, 23-24.	1.4	19
47	Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 2064-2068.	1.3	16
48	Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-7.	3.0	16
49	Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7501-7501.	1.6	16
50	Rituximab in Combination with Bendamustine or Chlorambucil for Treating Patients with Chronic Lymphocytic Leukemia: Interim Results of a Phase IIIb Study (MaBLE).. <i>Blood</i> , 2012, 120, 2744-2744.	1.4	16
51	Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 321.	8.6	15
52	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 255-263.	2.4	14
53	Chronic lymphocytic leukemia and the Warburg effect. <i>Blood</i> , 2015, 125, 3368-3369.	1.4	12
54	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 4696-4696.	1.4	12

#	ARTICLE	IF	CITATIONS
55	Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 548-555.e4.	0.4	10
56	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. <i>Annals of Hematology</i> , 2021, 100, 1733-1742.	1.8	10
57	Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 43.e1-43.e5.	1.2	10
58	Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 33-40.	2.5	9
59	Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. <i>Blood</i> , 2018, 132, 691-691.	1.4	8
60	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. <i>Leukemia and Lymphoma</i> , 2022, 63, 1375-1386.	1.3	8
61	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	1.8	7
62	FCγRIIb expression in early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2642-2648.	1.3	7
63	Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2823-2834.	2.5	7
64	When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). <i>Annals of Hematology</i> , 2020, 99, 157-165.	1.8	7
65	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	1.4	7
66	Is MRD eradication a desirable goal in CLL?. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 97-107.	1.7	6
67	The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. <i>Current Opinion in Oncology</i> , 2021, 33, 670-680.	2.4	6
68	Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib. <i>Blood</i> , 2020, 136, 32-33.	1.4	6
69	Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naïve CLL/SLL (PCYC-1130): iLLUMINATE.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS7095-TPS7095.	1.6	6
70	Comment on "Soluble BAFF Levels Inversely Correlate with Peripheral B Cell Numbers and the Expression of BAFF Receptors". <i>Journal of Immunology</i> , 2012, 188, 2930.2-2931.	0.8	5
71	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020, 105, e164-e168.	3.5	5
72	Autoimmune Cytopenia in CLL. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 286-296.	2.0	5

#	ARTICLE	IF	CITATIONS
73	Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE). <i>Blood</i> , 2020, 136, 25-26.	1.4	4
74	Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7519-7519.	1.6	4
75	Autoimmune cytopenia and CLL ride together. <i>Blood</i> , 2021, 137, 3464-3465.	1.4	3
76	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. <i>Blood</i> , 2018, 132, 5565-5565.	1.4	3
77	Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7012-7012.	1.6	3
78	Changes in clinical stage identify patients with <scp>CLL</scp> and different outcome within iw<scp>CLL</scp> partial response: <scp>RESONATE</scp> study. <i>British Journal of Haematology</i> , 2019, 185, 148-150.	2.5	2
79	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. <i>Blood</i> , 2018, 132, 1856-1856.	1.4	2
80	A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study. <i>Blood</i> , 2013, 122, 1645-1645.	1.4	2
81	Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. <i>Blood</i> , 2015, 126, 4146-4146.	1.4	2
82	A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. <i>Blood</i> , 2014, 124, 1976-1976.	1.4	2
83	Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC). <i>Blood</i> , 2019, 134, 4296-4296.	1.4	2
84	Challenges and Solutions for Collecting and Analyzing Real World Data: The Eric CLL Database as an Illustrative Example. <i>HemaSphere</i> , 2020, 4, e425.	2.7	2
85	MRD in CLL: some answers, many questions. <i>Blood</i> , 2021, 138, 2746-2747.	1.4	2
86	Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. <i>American Journal of Hematology</i> , 2017, 92, E132-E135.	4.1	1
87	Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 737-742.	0.4	1
88	Fc $\gamma$ RIIb-BCR coligation inhibits BCR signaling in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 106, 306-309.	3.5	1
89	Over 20% of Patients with Chronic Lymphocytic Leukemia Carry Stereotyped Receptors: Pathogenetic Implications and Clinical Correlations.. <i>Blood</i> , 2006, 108, 26-26.	1.4	1
90	Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis. <i>Blood</i> , 2015, 126, 3209-3209.	1.4	1

#	ARTICLE	IF	CITATIONS
91	The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.. Journal of Clinical Oncology, 2018, 36, 7533-7533.	1.6	1
92	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.. Journal of Clinical Oncology, 2019, 37, 7510-7510.	1.6	1
93	Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia (CLL) In Clinical Practice: A European Research Initiative On CLL (ERIC) Survey. Blood, 2013, 122, 4156-4156.	1.4	1
94	Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. Blood, 2019, 134, 4287-4287.	1.4	1
95	Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study. Blood, 2021, 138, 1561-1561.	1.4	1
96	Gene expression workflow to analyze residual leukemic cells in Chronic Lymphocytic Leukemia. International Journal of Laboratory Hematology, 2020, 42, 423-430.	1.3	0
97	Nucleotide Insertions and Deletions in Chronic Lymphocytic Leukemia. A CLL Specific Deletion among IGHV3-21 Expressing Cases with Stereotyped Receptors.. Blood, 2005, 106, 2100-2100.	1.4	0
98	A Different Ontogenesis for CLL Cases Carrying Stereotyped Antigen Receptors: Molecular and Computational Evidence. Blood, 2008, 112, 777-777.	1.4	0
99	The Prognostic Significance of Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 2361-2361.	1.4	0
100	Long-Term Follow-Up Of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation For High Risk Follicular Lymphoma. Blood, 2013, 122, 5519-5519.	1.4	0
101	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3300-3300.	1.4	0
102	Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2016, 128, 4663-4663.	1.4	0
103	Changes in Clinical Stage Identify Different Response Categories Among Patients in Iwcll PR: Analysis of CLL Patients on the Resonate Study. Blood, 2016, 128, 4384-4384.	1.4	0
104	Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT. Blood, 2016, 128, 3504-3504.	1.4	0
105	Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).. Journal of Clinical Oncology, 2018, 36, 7521-7521.	1.6	0